Tranexamic Acid for the Management of Obstetric Hemorrhage
Obstetric hemorrhage remains the most common cause of maternal mortality worldwide. It is believed that increased fibrinolytic activity, secondary to release and activation of endothelial tissue plasminogen activator, is involved in its pathogenesis. Tranexamic acid (TXA), an antifibrinolytic agent, has been shown to be beneficial in trauma patients if used within 3 hours of injury. A recent large randomized controlled trial showed that TXA given to hemorrhaging women within 3 hours after delivery was associated with decreased risk of death resulting from bleeding with no increase in thromboembolic complications. Limited evidence suggests that prophylactic TXA reduces blood loss at the time of delivery and decreases transfusion rates in the obstetric population. Tranexamic acid appears to be a safe and effective option in the treatment of obstetric hemorrhage. In addition, the limited available evidence supports the need for a well-designed adequately powered clinical trial to test its benefit as a prophylactic agent.
| Errataetall: |
CommentIn: Obstet Gynecol. 2017 Dec;130(6):1386. - PMID 29189683 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
Obstetrics and gynecology - 130(2017), 4 vom: 01. Okt., Seite 765-769 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pacheco, Luis D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6T84R30KC1 |
|---|
| Anmerkungen: |
Date Completed 29.09.2017 Date Revised 08.01.2021 published: Print CommentIn: Obstet Gynecol. 2017 Dec;130(6):1386. - PMID 29189683 Citation Status MEDLINE |
|---|
| doi: |
10.1097/AOG.0000000000002253 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM275567915 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM275567915 | ||
| 003 | DE-627 | ||
| 005 | 20231225005952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/AOG.0000000000002253 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0918.xml |
| 035 | |a (DE-627)NLM275567915 | ||
| 035 | |a (NLM)28885402 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pacheco, Luis D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tranexamic Acid for the Management of Obstetric Hemorrhage |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2017 | ||
| 500 | |a Date Revised 08.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Obstet Gynecol. 2017 Dec;130(6):1386. - PMID 29189683 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Obstetric hemorrhage remains the most common cause of maternal mortality worldwide. It is believed that increased fibrinolytic activity, secondary to release and activation of endothelial tissue plasminogen activator, is involved in its pathogenesis. Tranexamic acid (TXA), an antifibrinolytic agent, has been shown to be beneficial in trauma patients if used within 3 hours of injury. A recent large randomized controlled trial showed that TXA given to hemorrhaging women within 3 hours after delivery was associated with decreased risk of death resulting from bleeding with no increase in thromboembolic complications. Limited evidence suggests that prophylactic TXA reduces blood loss at the time of delivery and decreases transfusion rates in the obstetric population. Tranexamic acid appears to be a safe and effective option in the treatment of obstetric hemorrhage. In addition, the limited available evidence supports the need for a well-designed adequately powered clinical trial to test its benefit as a prophylactic agent | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antifibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Tranexamic Acid |2 NLM | |
| 650 | 7 | |a 6T84R30KC1 |2 NLM | |
| 700 | 1 | |a Hankins, Gary D V |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Antonio F |e verfasserin |4 aut | |
| 700 | 1 | |a Costantine, Maged M |e verfasserin |4 aut | |
| 700 | 1 | |a Chiossi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Saade, George R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obstetrics and gynecology |d 1953 |g 130(2017), 4 vom: 01. Okt., Seite 765-769 |w (DE-627)NLM000021555 |x 1873-233X |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2017 |g number:4 |g day:01 |g month:10 |g pages:765-769 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/AOG.0000000000002253 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2017 |e 4 |b 01 |c 10 |h 765-769 | ||